Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey
Abstract
:1. Introduction
2. Materials and Methods
3. Results
3.1. First Dose
3.2. Second Dose
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Statement
Abbreviations
ECDC | European Centre for Disease Prevention and Control |
MMR | Measles, mumps, rubella |
IS 2018 | Immunological Survey 2018 |
References
- Venkatesan, P. Worrying global decline in measles immunisation. Lancet Microbe 2022, 3, e9. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization. Measles and Rubella Strategic Framework: 2021–2030. 2020. Available online: https://apps.who.int/iris/handle/10665/339801 (accessed on 21 February 2025).
- Novilla, M.L.B.; Goates, M.C.; Redelfs, A.H.; Quenzer, M.; Novilla, L.K.B.; Leffler, T.; Holt, C.A.; Doria, R.B.; Dang, M.T.; Hewitt, M.; et al. Why Parents Say No to Having Their Children Vaccinated against Measles: A Systematic Review of the Social Determinants of Parental Perceptions on MMR Vaccine Hesitancy. Vaccines 2023, 11, 926. [Google Scholar] [CrossRef] [PubMed]
- Eagan, R.L.; Larson, H.J.; de Figueiredo, A. Recent trends in vaccine coverage and confidence: A cause for concern. Hum. Vaccines Immunother. 2023, 19, 2237374. [Google Scholar] [CrossRef]
- Zibolenová, J.; Hudečková, H.; Chladná, Z.; Malobická, E.; Novák, M.; Waczulíková, I.; Mikas, J.; Mečochová, A. Quantification of Waning Immunity After Measles Vaccination-Evidence from a Seroprevalence Study. Am. J. Epidemiol. 2023, 192, 1379–1385. [Google Scholar] [CrossRef] [PubMed]
- Akmatov, M.K.; Kretzschmar, M.; Krämer, A.; Mikolajczyk, R.T. Timeliness of vaccination and its effects on fraction of vaccinated population. Vaccine 2008, 26, 3805–3811. [Google Scholar] [CrossRef] [PubMed]
- Leuridan, E.; Hens, N.; Hutse, V.; Ieven, M.; Aerts, M.; Van Damme, P. Early waning of maternal measles antibodies in era of measles elimination: Longitudinal study. BMJ (Clin. Res. Ed.) 2010, 340, c1626. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; O’Driscoll, M.; Wang, Q.; Zhao, S.; Salje, H.; Yu, H. Dynamics of measles immunity from birth and following vaccination. Nat. Microbiol. 2024, 9, 1676–1685. [Google Scholar] [CrossRef] [PubMed]
- Goult, E.; Barrero Guevara, L.A.; Briga, M.; Domenech de Cellès, M. Estimating the optimal age for infant measles vaccination. Nat. Commun. 2024, 15, 9919. [Google Scholar] [CrossRef] [PubMed]
- European Centre for Disease Prevention and Control. Vaccine Scheduler. Measles: Recommended Vaccinations. 2025. Available online: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=-1 (accessed on 21 February 2025).
- Public Health Authority of the Slovak Republic. Imunologický Prehľad v Slovenskej Republike v Roku 2018. [Immunological Survey in the Slovak Republic in 2018]. 2018. Available online: https://ssvpl.sk/wp-content/uploads/2019/08/Imunologick%C3%BD-preh%C4%BEad-v-Slovenskej-republike-v-roku-2018.pdf (accessed on 21 February 2025).
- Ministry of Health of the Slovak Republic. Decree No. 585/2008 Coll., Which Establishes Details on the Prevention and Control of Communicable Diseases. 2008. Available online: https://www.slov-lex.sk/pravne-predpisy/SK/ZZ/2008/585/20200101 (accessed on 21 February 2025).
- European Centre for Disease Prevention and Control. (28 May 2019). Who Is at Risk of Measles in the EU/EEA? Identifying Susceptible Groups to Close Immunity Gaps Towards Measles Elimination. Available online: https://www.ecdc.europa.eu/en/publications-data/risk-assessment-measles-eu-eea-2019 (accessed on 21 February 2025).
- European Centre for Disease Prevention and Control. Measles. In Annual Epidemiological Report for 2023; ECDC: Stockholm, Sweden, 2024. [Google Scholar]
- Centers for Disease Control and Prevention. Measles Vaccination. 2025. Available online: https://www.cdc.gov/measles/vaccines/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fvpd%2Fmmr%2Fpublic%2Findex.html#cdc_vaccine_basics_resources-resources (accessed on 21 February 2025).
- Public Health Authority of the Slovak Republic: Updated Guidance of the Chief Hygienist of the Slovak Republic on the Action Plan for Maintaining the Elimination Status of Measles and Congenital Rubella Syndrome and for the Elimination of Rubella in the Slovak Republic, 23 April 2019. Available online: https://ssvpl.sk/aktualizovane-usmernenie/ (accessed on 21 February 2025).
- Choudhary, T.S.; Reddy, N.S.; Apte, A.; Sinha, B.; Roy, S.; Nair, N.P.; Sindhu, K.N.; Patil, R.; Upadhyay, R.P.; Chowdhury, R. Delayed vaccination and its predictors among children under 2 years in India: Insights from the national family health survey-4. Vaccine 2019, 37, 2331–2339. [Google Scholar] [CrossRef] [PubMed]
- Mayerová, D.; Abbas, K. Childhood immunisation timeliness and vaccine confidence by health information source, maternal, socioeconomic, and geographic characteristics in Albania. BMC Public Health 2021, 21, 1724. [Google Scholar] [CrossRef]
- Kirkedal, A.-B.K.; Møller, J.E.; Stensballe, L.G.; Zoffmann, V. Parents’ and Health Professionals’ Attitudes to Advancing Primary MMR Vaccine Administration from Fifteen to Six Months of Age—A Qualitative Thematic Analysis Embedded in a Randomized Trial. Vaccines 2023, 11, 67. [Google Scholar] [CrossRef] [PubMed]
- Tabacchi, G.; Costantino, C.; Napoli, G.; Marchese, V.; Cracchiolo, M.; Casuccio, A.; Vitale, F. The Esculapio Working Group Determinants of European parents’ decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. Hum. Vaccines Immunother. 2016, 12, 1909–1923. [Google Scholar] [CrossRef]
- Kanakoudi-Tsakalidou, F.; Farmaki, E.; Papadimitriou, E.; Taparkou, A.; Agakidou, E.; Glykou, S.; Papachristou, F. Humoral Immunity against Measles in Mother–Infant Pairs during the First Year of Life in Greece: A Cross-Sectional Study. Vaccines 2021, 9, 143. [Google Scholar] [CrossRef] [PubMed]
- Minta, A.A.; Ferrari, M.; Antoni, S.; Lambert, B.; Sayi, T.S.; Hsu, C.H.; Steulet, C.; Gacic-Dobo, M.; Rota, P.A.; Mulders, M.N.; et al. Progress Toward Measles Elimination—Worldwide, 2000–2023. MMWR Morb. Mortal. Wkly. Rep. 2024, 73, 1036–1042. [Google Scholar] [CrossRef] [PubMed]
- Simone, B.; Carrillo-Santisteve, P.; Lopalco, P.L. Healthcare workers role in keeping MMR vaccination uptake high in Europe: A review of evidence. Euro Surveill.: Bull. Eur. Sur Les Mal. Transm.=Eur. Commun. Dis. Bull. 2012, 17, 20206. [Google Scholar]
Total (Birth Cohorts 1995–2018) | 2713 | 100.0% |
---|---|---|
1st dose | ||
Unvaccinated due to age (less than 15th month) | 13 | 0.5% |
Unvaccinated (15th–18th month) | 28 | 1.0% |
Unvaccinated (more than 18th month) | 24 | 0.9% |
Unknown vaccination status for 1st dose | 18 | 0.7% |
Vaccinated, unknown date | 70 | 2.6% |
Vaccinated, known date | 2560 | 94.4% |
2nd dose | ||
Unvaccinated due to age (less than 11th year) | 1469 | 54.1% |
Unvaccinated (11th year) | 71 | 2.6% |
Unvaccinated (more than 11th year) | NA | NA |
Unknown vaccination status for 2nd dose | 55 | 2.0% |
Vaccinated, unknown date | 57 | 2.1% |
Vaccinated, known date | 1061 | 39.1% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zibolenová, J.; Ulbrichtová, R.; Malobická, E.; Novák, M.; Baška, T.; Časnocha Lúčanová, L.; Mikas, J.; Mečochová, A.; Hudečková, H. Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey. Vaccines 2025, 13, 382. https://doi.org/10.3390/vaccines13040382
Zibolenová J, Ulbrichtová R, Malobická E, Novák M, Baška T, Časnocha Lúčanová L, Mikas J, Mečochová A, Hudečková H. Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey. Vaccines. 2025; 13(4):382. https://doi.org/10.3390/vaccines13040382
Chicago/Turabian StyleZibolenová, Jana, Romana Ulbrichtová, Eva Malobická, Martin Novák, Tibor Baška, Lucia Časnocha Lúčanová, Ján Mikas, Adriana Mečochová, and Henrieta Hudečková. 2025. "Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey" Vaccines 13, no. 4: 382. https://doi.org/10.3390/vaccines13040382
APA StyleZibolenová, J., Ulbrichtová, R., Malobická, E., Novák, M., Baška, T., Časnocha Lúčanová, L., Mikas, J., Mečochová, A., & Hudečková, H. (2025). Timing of Measles, Mumps, and Rubella Vaccination: Secondary Outcomes from an Immunological Survey. Vaccines, 13(4), 382. https://doi.org/10.3390/vaccines13040382